143 related articles for article (PubMed ID: 34308004)
1. Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An
Akinlalu AO; Chamundi A; Yakumbur DT; Afolayan FID; Duru IA; Arowosegbe MA; Enejoh OA
Sci Afr; 2021 Sep; 13():e00845. PubMed ID: 34308004
[TBL] [Abstract][Full Text] [Related]
2. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
3. In silico identification of compounds from
Duru CE; Duru IA; Adegboyega AE
Bull Natl Res Cent; 2021; 45(1):57. PubMed ID: 33727782
[TBL] [Abstract][Full Text] [Related]
4. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.
Udofia IA; Gbayo KO; Oloba-Whenu OA; Ogunbayo TB; Isanbor C
Netw Model Anal Health Inform Bioinform; 2021; 10(1):22. PubMed ID: 33786291
[TBL] [Abstract][Full Text] [Related]
5. Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.
Singh SK; Upadhyay AK; Reddy MS
3 Biotech; 2021 Feb; 11(2):93. PubMed ID: 33520579
[TBL] [Abstract][Full Text] [Related]
6.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
7. Metabologenomics approach to the discovery of novel compounds from
Melinda YN; Widada J; Wahyuningsih TD; Febriansah R; Damayanti E; Mustofa M
Heliyon; 2021 Nov; 7(11):e08308. PubMed ID: 34746476
[TBL] [Abstract][Full Text] [Related]
8. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
[TBL] [Abstract][Full Text] [Related]
9. Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study.
Rameshkumar MR; Indu P; Arunagirinathan N; Venkatadri B; El-Serehy HA; Ahmad A
Saudi J Biol Sci; 2021 Jan; 28(1):448-458. PubMed ID: 33110386
[TBL] [Abstract][Full Text] [Related]
10. Silybin B and Cianidanol Inhibit M
Srivastava R; Tripathi S; Unni S; Hussain A; Haque S; Dasgupta N; Singh V; Mishra BN
Curr Pharm Des; 2021; 27(32):3476-3489. PubMed ID: 33302853
[TBL] [Abstract][Full Text] [Related]
11. The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp.
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Saudi J Biol Sci; 2021 Feb; 28(2):1426-1432. PubMed ID: 33281478
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking of ethanol extracts of katuk leaf (
Makati AC; Ananda AN; Putri JA; Amellia SF; Setiawan B
S Afr J Bot; 2022 Sep; 149():1-5. PubMed ID: 35668920
[TBL] [Abstract][Full Text] [Related]
13. Anti-COVID-19 activity of some benzofused 1,2,3-triazolesulfonamide hybrids using
Alzahrani AY; Shaaban MM; Elwakil BH; Hamed MT; Rezki N; Aouad MR; Zakaria MA; Hagar M
Chemometr Intell Lab Syst; 2021 Oct; 217():104421. PubMed ID: 34538993
[TBL] [Abstract][Full Text] [Related]
14. In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19.
Adegbola PI; Fadahunsi OS; Adegbola AE; Semire B
In Silico Pharmacol; 2021; 9(1):45. PubMed ID: 34312587
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach.
Zapata-Cardona MI; Florez-Alvarez L; Guerra-Sandoval AL; Chvatal-Medina M; Guerra-Almonacid CM; Hincapie-Garcia J; Hernandez JC; Rugeles MT; Zapata-Builes W
AIMS Microbiol; 2023; 9(1):20-40. PubMed ID: 36891537
[TBL] [Abstract][Full Text] [Related]
16. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
Wakchaure PD; Ghosh S; Ganguly B
J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
[TBL] [Abstract][Full Text] [Related]
17. In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex.
Buitrón-González I; Aguilera-Durán G; Romo-Mancillas A
Results Chem; 2021 Jan; 3():100094. PubMed ID: 33520633
[TBL] [Abstract][Full Text] [Related]
18. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
[TBL] [Abstract][Full Text] [Related]
19. Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic.
Muteeb G; Alshoaibi A; Aatif M; Rehman MT; Qayyum MZ
Appl Biol Chem; 2020; 63(1):79. PubMed ID: 33251389
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an
Elfiky AA
J Biomol Struct Dyn; 2021 Jun; 39(9):3204-3212. PubMed ID: 32338164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]